source
- Another Paragon offshoot chooses reverse merger, this time for migraine drugsThey say stick to what you know. And Paragon Therapeutics knows how to do reverse mergers. The hub-and-spoke biologics company is moving its migraine drug offshoot, Mentari Therapeutics, onto the p…Endpoints · 2mo ago↗ source
- Acceleron leaders and Westlake jumpstart new IPF biotechAfter success with the drug Winrevair, a band of entrepreneurs has found their next challenge in a difficult-to-treat lung disease. On Tuesday, Oorja Bio launched with a $30 million Series A round,…Endpoints · 2mo ago↗ source
- STAT+: Canadian medical societies lack sufficient conflict-of-interest policies, study findsMost Canadian medical societies lack comprehensive policies governing conflicts of interest, and many policies are generally fragmented and narrow in scope, according to a new analysis.